REG - GSK Capital B.V. GSK PLC - Publication of Final Terms of EMTN Notes

GSKAnnouncement

25/11/2022 17:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221125:nRSY6838Ha&default-theme=true

RNS Number : 6838H  GSK Capital B.V.  25 November 2022

Issued: 25 November 2022, London UK - LSE Announcement

Publication of Final Terms

GSK Capital B.V. announces that the following final terms dated 25 November
2022 (the "Final Terms") in respect of the Notes (as defined below) are
available for viewing:

GSK Capital B.V. issue of:

EUR 500,000,000 3.000% Notes due 2027; and

EUR 750,000,000 3.125% Notes due 2032.

in each case guaranteed by GSK plc issued under the £20,000,000,000 Euro
Medium Term Note Programme (the "Notes")

Copies of the Final Terms have been submitted to the Financial Conduct
Authority's NSM submission portal via the Electronic Submission System (ESS).
A copy can be viewed at:

https://data.fca.org.uk/#/nsm/nationalstoragemechanism
(https://data.fca.org.uk/#/nsm/nationalstoragemechanism)

For further information, please contact:

GSK plc

980 Great West Road

Brentford

Middlesex

TW8 9GS

United Kingdom

Enquiries:

 UK Media enquiries:                   Tim Foley       +44 (0) 20 8047 5564

(London)
 European Analyst/Investor enquiries:  Nick Stone      +44 (0) 7717 618 834

(London)

James Dodwell
+44 (0) 7881 269 066

(London)

 

BASIS ON WHICH YOU MAY ACCESS THE FINAL TERMS AND PROSPECTUS

Please note that the information contained in the Final Terms and the
Prospectus may be addressed to and/or targeted at persons who are residents of
particular countries (specified in the Prospectus) only and is not intended
for use and should not be relied upon by any person outside these countries
and/or to whom the offer contained in the Final Terms is not addressed. Prior
to relying on the information contained in the Final Terms or the Prospectus
you must ascertain from the Prospectus whether or not you are part of the
intended addressees of the information contained therein.

Your right to access this service is conditional upon complying with the above
requirements.

 GSK Capital B.V.

 Registered in the Netherlands and in the UK as an overseas company:

 No. FC038264

 Registered UK establishment:

 980 Great West Road

 Brentford, Middlesex

 TW8 9GS

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  PFTBLBDBDSDDGDU